Recursion Pharmaceuticals, Inc. $RXRX Holdings Increased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. increased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 724.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,704 shares of the company’s stock after purchasing an additional 86,730 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Recursion Pharmaceuticals were worth $499,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Recursion Pharmaceuticals by 183.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock worth $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Recursion Pharmaceuticals by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company’s stock worth $4,566,000 after purchasing an additional 12,588 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $67,000. Advisors Asset Management Inc. raised its holdings in shares of Recursion Pharmaceuticals by 753.8% in the 1st quarter. Advisors Asset Management Inc. now owns 133,485 shares of the company’s stock worth $706,000 after purchasing an additional 117,851 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Stock Down 0.3%

RXRX stock opened at $5.73 on Friday. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company’s 50 day simple moving average is $5.17 and its 200-day simple moving average is $5.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The firm has a market capitalization of $2.49 billion, a P/E ratio of -3.22 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. During the same quarter in the prior year, the firm earned ($0.40) EPS. The firm’s revenue was up 33.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.